世界の抗高眼圧症薬市場インサイト及び予測(αアゴニスト、βブロッカー、プロスタグランジンアナログ、その他)

◆英語タイトル:Global Anti-intraocular Hypertension Drugs Market Insights, Forecast to 2028

QYResearchが発行した調査報告書(QY22JLX10361)◆商品コード:QY22JLX10361
◆発行会社(リサーチ会社):QYResearch
◆発行日:2022年7月(※2025年版があります。お問い合わせください。)
◆ページ数:113
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥744,800見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,117,200見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,489,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、抗高眼圧症薬のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に抗高眼圧症薬の世界市場のxxx%を占める「αアゴニスト」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「病院薬局」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
抗高眼圧症薬の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパの抗高眼圧症薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

抗高眼圧症薬のグローバル主要企業には、Allergen、Novartis、Santen Pharmaceutical、Akorn、AGC Chemicals、Pfizer、Emmennar、Baush Health Companies、Aerie Pharmaceuticals、Senju Pharmaceuticals、Zydus Cadila、Johnson、Merck、China Resources Zizhu Pharmaceutical、Sun Ophthalmics、Bayer、Hengrui Pharma、Ausun Pharmaceuticalなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

抗高眼圧症薬市場は、種類と用途によって区分されます。世界の抗高眼圧症薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
αアゴニスト、βブロッカー、プロスタグランジンアナログ、その他

【用途別セグメント】
病院薬局、小売薬局、オンライン薬局

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- 抗高眼圧症薬製品概要
- 種類別市場(αアゴニスト、βブロッカー、プロスタグランジンアナログ、その他)
- 用途別市場(病院薬局、小売薬局、オンライン薬局)
- 調査の目的
・エグゼクティブサマリー
- 世界の抗高眼圧症薬販売量予測2017-2028
- 世界の抗高眼圧症薬売上予測2017-2028
- 抗高眼圧症薬の地域別販売量
- 抗高眼圧症薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別抗高眼圧症薬販売量
- 主要メーカー別抗高眼圧症薬売上
- 主要メーカー別抗高眼圧症薬価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(αアゴニスト、βブロッカー、プロスタグランジンアナログ、その他)
- 抗高眼圧症薬の種類別販売量
- 抗高眼圧症薬の種類別売上
- 抗高眼圧症薬の種類別価格
・用途別市場規模(病院薬局、小売薬局、オンライン薬局)
- 抗高眼圧症薬の用途別販売量
- 抗高眼圧症薬の用途別売上
- 抗高眼圧症薬の用途別価格
・北米市場
- 北米の抗高眼圧症薬市場規模(種類別、用途別)
- 主要国別の抗高眼圧症薬市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパの抗高眼圧症薬市場規模(種類別、用途別)
- 主要国別の抗高眼圧症薬市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋の抗高眼圧症薬市場規模(種類別、用途別)
- 主要国別の抗高眼圧症薬市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米の抗高眼圧症薬市場規模(種類別、用途別)
- 主要国別の抗高眼圧症薬市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカの抗高眼圧症薬市場規模(種類別、用途別)
- 主要国別の抗高眼圧症薬市場規模(トルコ、サウジアラビア)
・企業情報
Allergen、Novartis、Santen Pharmaceutical、Akorn、AGC Chemicals、Pfizer、Emmennar、Baush Health Companies、Aerie Pharmaceuticals、Senju Pharmaceuticals、Zydus Cadila、Johnson、Merck、China Resources Zizhu Pharmaceutical、Sun Ophthalmics、Bayer、Hengrui Pharma、Ausun Pharmaceutical
・産業チェーン及び販売チャネル分析
- 抗高眼圧症薬の産業チェーン分析
- 抗高眼圧症薬の原材料
- 抗高眼圧症薬の生産プロセス
- 抗高眼圧症薬の販売及びマーケティング
- 抗高眼圧症薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 抗高眼圧症薬の産業動向
- 抗高眼圧症薬のマーケットドライバー
- 抗高眼圧症薬の課題
- 抗高眼圧症薬の阻害要因
・主な調査結果

Anti-intraocular hypertension drugs are medications that can treat high intraocular pressure.
Market Analysis and Insights: Global Anti-intraocular Hypertension Drugs Market
Due to the COVID-19 pandemic, the global Anti-intraocular Hypertension Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Alpha Agonist accounting for % of the Anti-intraocular Hypertension Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period.
China Anti-intraocular Hypertension Drugs market size is valued at US$ million in 2021, while the US and Europe Anti-intraocular Hypertension Drugs are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Anti-intraocular Hypertension Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Anti-intraocular Hypertension Drugs include Allergen, Novartis, Santen Pharmaceutical, Akorn, AGC Chemicals, Pfizer, Emmennar, Baush Health Companies and Aerie Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Anti-intraocular Hypertension Drugs Scope and Segment
Anti-intraocular Hypertension Drugs market is segmented by Type and by Distribution Channel. Players, stakeholders, and other participants in the global Anti-intraocular Hypertension Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Distribution Channel for the period 2017-2028.
Segment by Type
Alpha Agonist
Beta Blockers
Prostaglandin Analogs
Others
Segment by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Company
Allergen
Novartis
Santen Pharmaceutical
Akorn
AGC Chemicals
Pfizer
Emmennar
Baush Health Companies
Aerie Pharmaceuticals
Senju Pharmaceuticals
Zydus Cadila
Johnson
Merck
China Resources Zizhu Pharmaceutical
Sun Ophthalmics
Bayer
Hengrui Pharma
Ausun Pharmaceutical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 Anti-intraocular Hypertension Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Anti-intraocular Hypertension Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Alpha Agonist
1.2.3 Beta Blockers
1.2.4 Prostaglandin Analogs
1.2.5 Others
1.3 Market by Distribution Channel
1.3.1 Global Anti-intraocular Hypertension Drugs Market Size Growth Rate by Distribution Channel, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Anti-intraocular Hypertension Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Anti-intraocular Hypertension Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Anti-intraocular Hypertension Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Anti-intraocular Hypertension Drugs Sales by Region
2.4.1 Global Anti-intraocular Hypertension Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Anti-intraocular Hypertension Drugs by Region (2023-2028)
2.5 Global Anti-intraocular Hypertension Drugs Revenue by Region
2.5.1 Global Anti-intraocular Hypertension Drugs Revenue by Region (2017-2022)
2.5.2 Global Anti-intraocular Hypertension Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Anti-intraocular Hypertension Drugs Sales by Manufacturers
3.1.1 Global Top Anti-intraocular Hypertension Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Anti-intraocular Hypertension Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Anti-intraocular Hypertension Drugs in 2021
3.2 Global Anti-intraocular Hypertension Drugs Revenue by Manufacturers
3.2.1 Global Anti-intraocular Hypertension Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Anti-intraocular Hypertension Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Anti-intraocular Hypertension Drugs Revenue in 2021
3.3 Global Anti-intraocular Hypertension Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Anti-intraocular Hypertension Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Anti-intraocular Hypertension Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Anti-intraocular Hypertension Drugs Sales by Type
4.1.1 Global Anti-intraocular Hypertension Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Anti-intraocular Hypertension Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Anti-intraocular Hypertension Drugs Sales Market Share by Type (2017-2028)
4.2 Global Anti-intraocular Hypertension Drugs Revenue by Type
4.2.1 Global Anti-intraocular Hypertension Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Anti-intraocular Hypertension Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Anti-intraocular Hypertension Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Anti-intraocular Hypertension Drugs Price by Type
4.3.1 Global Anti-intraocular Hypertension Drugs Price by Type (2017-2022)
4.3.2 Global Anti-intraocular Hypertension Drugs Price Forecast by Type (2023-2028)
5 Market Size by Distribution Channel
5.1 Global Anti-intraocular Hypertension Drugs Sales by Distribution Channel
5.1.1 Global Anti-intraocular Hypertension Drugs Historical Sales by Distribution Channel (2017-2022)
5.1.2 Global Anti-intraocular Hypertension Drugs Forecasted Sales by Distribution Channel (2023-2028)
5.1.3 Global Anti-intraocular Hypertension Drugs Sales Market Share by Distribution Channel (2017-2028)
5.2 Global Anti-intraocular Hypertension Drugs Revenue by Distribution Channel
5.2.1 Global Anti-intraocular Hypertension Drugs Historical Revenue by Distribution Channel (2017-2022)
5.2.2 Global Anti-intraocular Hypertension Drugs Forecasted Revenue by Distribution Channel (2023-2028)
5.2.3 Global Anti-intraocular Hypertension Drugs Revenue Market Share by Distribution Channel (2017-2028)
5.3 Global Anti-intraocular Hypertension Drugs Price by Distribution Channel
5.3.1 Global Anti-intraocular Hypertension Drugs Price by Distribution Channel (2017-2022)
5.3.2 Global Anti-intraocular Hypertension Drugs Price Forecast by Distribution Channel (2023-2028)
6 North America
6.1 North America Anti-intraocular Hypertension Drugs Market Size by Type
6.1.1 North America Anti-intraocular Hypertension Drugs Sales by Type (2017-2028)
6.1.2 North America Anti-intraocular Hypertension Drugs Revenue by Type (2017-2028)
6.2 North America Anti-intraocular Hypertension Drugs Market Size by Distribution Channel
6.2.1 North America Anti-intraocular Hypertension Drugs Sales by Distribution Channel (2017-2028)
6.2.2 North America Anti-intraocular Hypertension Drugs Revenue by Distribution Channel (2017-2028)
6.3 North America Anti-intraocular Hypertension Drugs Market Size by Country
6.3.1 North America Anti-intraocular Hypertension Drugs Sales by Country (2017-2028)
6.3.2 North America Anti-intraocular Hypertension Drugs Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Anti-intraocular Hypertension Drugs Market Size by Type
7.1.1 Europe Anti-intraocular Hypertension Drugs Sales by Type (2017-2028)
7.1.2 Europe Anti-intraocular Hypertension Drugs Revenue by Type (2017-2028)
7.2 Europe Anti-intraocular Hypertension Drugs Market Size by Distribution Channel
7.2.1 Europe Anti-intraocular Hypertension Drugs Sales by Distribution Channel (2017-2028)
7.2.2 Europe Anti-intraocular Hypertension Drugs Revenue by Distribution Channel (2017-2028)
7.3 Europe Anti-intraocular Hypertension Drugs Market Size by Country
7.3.1 Europe Anti-intraocular Hypertension Drugs Sales by Country (2017-2028)
7.3.2 Europe Anti-intraocular Hypertension Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Anti-intraocular Hypertension Drugs Market Size by Type
8.1.1 Asia Pacific Anti-intraocular Hypertension Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Anti-intraocular Hypertension Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Anti-intraocular Hypertension Drugs Market Size by Distribution Channel
8.2.1 Asia Pacific Anti-intraocular Hypertension Drugs Sales by Distribution Channel (2017-2028)
8.2.2 Asia Pacific Anti-intraocular Hypertension Drugs Revenue by Distribution Channel (2017-2028)
8.3 Asia Pacific Anti-intraocular Hypertension Drugs Market Size by Region
8.3.1 Asia Pacific Anti-intraocular Hypertension Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Anti-intraocular Hypertension Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Anti-intraocular Hypertension Drugs Market Size by Type
9.1.1 Latin America Anti-intraocular Hypertension Drugs Sales by Type (2017-2028)
9.1.2 Latin America Anti-intraocular Hypertension Drugs Revenue by Type (2017-2028)
9.2 Latin America Anti-intraocular Hypertension Drugs Market Size by Distribution Channel
9.2.1 Latin America Anti-intraocular Hypertension Drugs Sales by Distribution Channel (2017-2028)
9.2.2 Latin America Anti-intraocular Hypertension Drugs Revenue by Distribution Channel (2017-2028)
9.3 Latin America Anti-intraocular Hypertension Drugs Market Size by Country
9.3.1 Latin America Anti-intraocular Hypertension Drugs Sales by Country (2017-2028)
9.3.2 Latin America Anti-intraocular Hypertension Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Anti-intraocular Hypertension Drugs Market Size by Type
10.1.1 Middle East and Africa Anti-intraocular Hypertension Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Anti-intraocular Hypertension Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Anti-intraocular Hypertension Drugs Market Size by Distribution Channel
10.2.1 Middle East and Africa Anti-intraocular Hypertension Drugs Sales by Distribution Channel (2017-2028)
10.2.2 Middle East and Africa Anti-intraocular Hypertension Drugs Revenue by Distribution Channel (2017-2028)
10.3 Middle East and Africa Anti-intraocular Hypertension Drugs Market Size by Country
10.3.1 Middle East and Africa Anti-intraocular Hypertension Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Anti-intraocular Hypertension Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Allergen
11.1.1 Allergen Corporation Information
11.1.2 Allergen Overview
11.1.3 Allergen Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Allergen Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Allergen Recent Developments
11.2 Novartis
11.2.1 Novartis Corporation Information
11.2.2 Novartis Overview
11.2.3 Novartis Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Novartis Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Novartis Recent Developments
11.3 Santen Pharmaceutical
11.3.1 Santen Pharmaceutical Corporation Information
11.3.2 Santen Pharmaceutical Overview
11.3.3 Santen Pharmaceutical Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Santen Pharmaceutical Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Santen Pharmaceutical Recent Developments
11.4 Akorn
11.4.1 Akorn Corporation Information
11.4.2 Akorn Overview
11.4.3 Akorn Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Akorn Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Akorn Recent Developments
11.5 AGC Chemicals
11.5.1 AGC Chemicals Corporation Information
11.5.2 AGC Chemicals Overview
11.5.3 AGC Chemicals Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 AGC Chemicals Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 AGC Chemicals Recent Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Overview
11.6.3 Pfizer Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Pfizer Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Pfizer Recent Developments
11.7 Emmennar
11.7.1 Emmennar Corporation Information
11.7.2 Emmennar Overview
11.7.3 Emmennar Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Emmennar Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Emmennar Recent Developments
11.8 Baush Health Companies
11.8.1 Baush Health Companies Corporation Information
11.8.2 Baush Health Companies Overview
11.8.3 Baush Health Companies Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Baush Health Companies Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Baush Health Companies Recent Developments
11.9 Aerie Pharmaceuticals
11.9.1 Aerie Pharmaceuticals Corporation Information
11.9.2 Aerie Pharmaceuticals Overview
11.9.3 Aerie Pharmaceuticals Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Aerie Pharmaceuticals Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Aerie Pharmaceuticals Recent Developments
11.10 Senju Pharmaceuticals
11.10.1 Senju Pharmaceuticals Corporation Information
11.10.2 Senju Pharmaceuticals Overview
11.10.3 Senju Pharmaceuticals Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Senju Pharmaceuticals Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Senju Pharmaceuticals Recent Developments
11.11 Zydus Cadila
11.11.1 Zydus Cadila Corporation Information
11.11.2 Zydus Cadila Overview
11.11.3 Zydus Cadila Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Zydus Cadila Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Zydus Cadila Recent Developments
11.12 Johnson
11.12.1 Johnson Corporation Information
11.12.2 Johnson Overview
11.12.3 Johnson Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Johnson Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Johnson Recent Developments
11.13 Merck
11.13.1 Merck Corporation Information
11.13.2 Merck Overview
11.13.3 Merck Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Merck Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Merck Recent Developments
11.14 China Resources Zizhu Pharmaceutical
11.14.1 China Resources Zizhu Pharmaceutical Corporation Information
11.14.2 China Resources Zizhu Pharmaceutical Overview
11.14.3 China Resources Zizhu Pharmaceutical Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 China Resources Zizhu Pharmaceutical Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 China Resources Zizhu Pharmaceutical Recent Developments
11.15 Sun Ophthalmics
11.15.1 Sun Ophthalmics Corporation Information
11.15.2 Sun Ophthalmics Overview
11.15.3 Sun Ophthalmics Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Sun Ophthalmics Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Sun Ophthalmics Recent Developments
11.16 Bayer
11.16.1 Bayer Corporation Information
11.16.2 Bayer Overview
11.16.3 Bayer Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Bayer Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Bayer Recent Developments
11.17 Hengrui Pharma
11.17.1 Hengrui Pharma Corporation Information
11.17.2 Hengrui Pharma Overview
11.17.3 Hengrui Pharma Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Hengrui Pharma Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Hengrui Pharma Recent Developments
11.18 Ausun Pharmaceutical
11.18.1 Ausun Pharmaceutical Corporation Information
11.18.2 Ausun Pharmaceutical Overview
11.18.3 Ausun Pharmaceutical Anti-intraocular Hypertension Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Ausun Pharmaceutical Anti-intraocular Hypertension Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Ausun Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Anti-intraocular Hypertension Drugs Industry Chain Analysis
12.2 Anti-intraocular Hypertension Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-intraocular Hypertension Drugs Production Mode & Process
12.4 Anti-intraocular Hypertension Drugs Sales and Marketing
12.4.1 Anti-intraocular Hypertension Drugs Sales Channels
12.4.2 Anti-intraocular Hypertension Drugs Distributors
12.5 Anti-intraocular Hypertension Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Anti-intraocular Hypertension Drugs Industry Trends
13.2 Anti-intraocular Hypertension Drugs Market Drivers
13.3 Anti-intraocular Hypertension Drugs Market Challenges
13.4 Anti-intraocular Hypertension Drugs Market Restraints
14 Key Findings in The Global Anti-intraocular Hypertension Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の抗高眼圧症薬市場インサイト及び予測(αアゴニスト、βブロッカー、プロスタグランジンアナログ、その他)(Global Anti-intraocular Hypertension Drugs Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。